




## Zilucoplan

Revised: November 15, 2023.

CASRN: 1841136-73-9



## Drug Levels and Effects

### Summary of Use during Lactation

Zilucoplan is expected to be degraded into small peptides and amino acids via catabolic pathways in the maternal circulation and infant gastrointestinal tract. It is unlikely to be absorbed by the breastfed infant or adversely affect the infant. No special precautions are required.

### Drug Levels

*Maternal Levels.* Relevant published information was not found as of the revision date.

*Infant Levels.* Relevant published information was not found as of the revision date.

---

**Disclaimer:** Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

**Attribution Statement:** LactMed is a registered trademark of the U.S. Department of Health and Human Services.

## Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

## Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

## Substance Identification

### Substance Name

Zilucoplan

### CAS Registry Number

1841136-73-9

### Drug Class

Breast Feeding

Lactation

Milk, Human

Complement Inactivating Agents